|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COMMENTS to the Centers for Medicare & Medicaid Services, U.S. Dept. of Health and Human Services, Concerning Non-Coverage of Cancer Drug Iressa (Gefitinib) Under Part DThe Lorenzen Cancer Foundation has joined the public interest law firm Washington Legal Foundation, the Abigail Alliance and the Lung Cancer Alliance in presenting comments to the Centers for Medicare & Medicaid Services concerning the labeling of Iressa (Gefitinib) under Part D.
Below is a link to the full text
copy of our comments to the Centers for Medicare & Medicaid
Services. Dale O’Brien, MD, MPH
Full Text of COMMENTS to the Food and Drug Administration (in PDF format): please click [Here] Link to the Washington Legal Foundation: please click [Here] Link to the Abigail Alliance: please click [Here] Link to the Lung Cancer Alliance: please click [Here]
|
 |
|
 Home | In The News | Links | Donations FAQ | Clinical Trials Registry | Research Resources | About Us |
|
|
|
|
|
www.pancreatica.org |